Workflow
财报分析
icon
Search documents
Alcon's Q2 Earnings Beat Estimates, Revenues Miss, Stock Plunges
ZACKS· 2025-08-21 15:16
Core Insights - Alcon, Inc. reported second-quarter 2025 core earnings per share (EPS) of 76 cents, a 2.7% increase year-over-year, exceeding the Zacks Consensus Estimate by 7.04% [1] - The company's net sales for the quarter were $2.58 billion, which fell short of the Zacks Consensus Estimate by 1.29%, but represented a 3.8% increase from the previous year [2] - Alcon's stock price dropped 10.1% following the earnings announcement [2] Revenue Breakdown - Alcon operates through two segments: Surgical and Vision Care [3] - Surgical sales reached $1.5 billion, a 2% increase year-over-year, with Implantables sales declining by 2% at constant exchange rates (CER) [4] - Vision Care segment reported total sales of $1.1 billion, up 6% year-over-year, driven by a 7% increase in Contact Lenses sales at CER [6] Margin Performance - The cost of net sales was $1.19 billion, up 7.9% year-over-year, leading to a gross profit of $1.38 billion, which rose by 0.5% [7] - Core gross margin contracted by 177 basis points to 53.5% [7] - Operating margin decreased by 245 basis points to 10.3% [9] Financial Position - Alcon ended Q2 2025 with cash and cash equivalents of $1.41 billion, consistent with the previous quarter [10] - Cumulative net cash flow from operating activities was $889 million, compared to $871 million in the same period last year [10] - Free cash flow totaled $681 million, up from $667 million in Q2 2024 [10] 2025 Outlook - The company revised its 2025 net sales outlook to $10.3-$10.4 billion, indicating a growth of 4%-5% at CER [11] - Core EPS guidance remains unchanged at $3.05-$3.15, with a revised growth forecast of 0%-2% from 2024 levels [12] Strategic Developments - Alcon is experiencing early demand for new products, which may enhance top-line growth and shareholder value [14] - The company announced a merger agreement to acquire STAAR Surgical, expanding its presence in myopia correction [14] - Alcon also acquired LumiThera and its Valeda Light Delivery System for treating dry age-related macular degeneration [14]
合众思壮(002383)2025年中报简析:营收上升亏损收窄,盈利能力上升
Zheng Quan Zhi Xing· 2025-08-21 11:10
财务报表中对有大幅变动的财务项目的原因说明如下: 证券之星价投圈财报分析工具显示: 业务评价:去年的净利率为-20.72%,算上全部成本后,公司产品或服务的附加值不高。从历史年 报数据统计来看,公司近10年来中位数ROIC为3.67%,中位投资回报较弱,其中最惨年份2020年 的ROIC为-17.08%,投资回报极差。公司历史上的财报非常一般,公司上市来已有年报14份,亏 损年份5次,如无借壳上市等因素,价投一般不看这类公司。 据证券之星公开数据整理,近期合众思壮(002383)发布2025年中报。截至本报告期末,公司营业总收入 6.59亿元,同比上升18.97%,归母净利润-907.21万元,同比上升84.29%。按单季度数据看,第二季度营 业总收入3.25亿元,同比上升13.19%,第二季度归母净利润-1175.88万元,同比上升51.95%。本报告期 合众思壮盈利能力上升,毛利率同比增幅0.13%,净利率同比增幅80.3%。 本次财报公布的各项数据指标表现尚佳。其中,毛利率41.52%,同比增0.48%,净利率-2.22%,同比增 80.3%,销售费用、管理费用、财务费用总计2.33亿元,三费占营收比3 ...
晋西车轴(600495)2025年中报简析:营收净利润同比双双增长,应收账款上升
Zheng Quan Zhi Xing· 2025-08-21 01:09
据证券之星公开数据整理,近期晋西车轴(600495)发布2025年中报。截至本报告期末,公司营业总收入 6.08亿元,同比上升41.73%,归母净利润1390.09万元,同比上升170.08%。按单季度数据看,第二季度 营业总收入2.35亿元,同比上升27.26%,第二季度归母净利润608.2万元,同比上升60.91%。本报告期 晋西车轴应收账款上升,应收账款同比增幅达100.02%。 本次财报公布的各项数据指标表现尚佳。其中,毛利率11.88%,同比增156.36%,净利率2.29%,同比 增149.45%,销售费用、管理费用、财务费用总计3835.84万元,三费占营收比6.31%,同比减27.26%, 每股净资产2.7元,同比增1.17%,每股经营性现金流-0.01元,同比增89.48%,每股收益0.01元,同比增 150.0% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 4.29亿 | 6.08亿 | liv 41.73% | | 归母净利润(元) | -1983.55万 | 1390.09万 | 17 ...
合百集团2025年中报简析:增收不增利,公司应收账款体量较大
Zheng Quan Zhi Xing· 2025-08-20 23:08
财务报表中对有大幅变动的财务项目的原因说明如下: 财务费用变动幅度为51.84%,原因:本报告期存款利率下行,利息收入减少。 经营活动产生的现金流量净额变动幅度为-242.58%,原因:本报告期收到销售商品款项减少。 据证券之星公开数据整理,近期合百集团(000417)发布2025年中报。截至本报告期末,公司营业总收 入37.0亿元,同比上升0.02%,归母净利润1.71亿元,同比下降9.93%。按单季度数据看,第二季度营业 总收入15.68亿元,同比下降7.69%,第二季度归母净利润9560.28万元,同比上升13.14%。本报告期合 百集团公司应收账款体量较大,当期应收账款占最新年报归母净利润比达139.47%。 本次财报公布的各项数据指标表现一般。其中,毛利率25.06%,同比减9.92%,净利率5.63%,同比减 10.79%,销售费用、管理费用、财务费用总计7.4亿元,三费占营收比19.99%,同比增2.23%,每股净资 产6.14元,同比增0.1%,每股经营性现金流-0.57元,同比减242.58%,每股收益0.22元,同比减9.91% | 项目 | 2024年中报 | 2025年中报 | 同比增 ...
天奥电子2025年中报简析:净利润同比下降46.25%,公司应收账款体量较大
Zheng Quan Zhi Xing· 2025-08-20 23:08
Core Viewpoint - Tian'ao Electronics (002935) reported disappointing financial results for the first half of 2025, with significant declines in revenue and net profit compared to the previous year [1] Financial Performance Summary - Total revenue for the first half of 2025 was 318 million yuan, a decrease of 16.09% year-on-year [1] - Net profit attributable to shareholders was 8.31 million yuan, down 46.25% year-on-year [1] - In Q2 2025, total revenue was 226 million yuan, a decline of 16.74% year-on-year, with net profit of 14.73 million yuan, down 40.03% year-on-year [1] - Gross margin was 24.08%, a decrease of 3.1% year-on-year, while net margin fell to 2.62%, down 35.94% year-on-year [1] - Total operating expenses (selling, administrative, and financial) amounted to 46 million yuan, accounting for 14.48% of revenue, an increase of 3.52% year-on-year [1] Cash Flow and Receivables - Operating cash flow per share was 0.06 yuan, a significant decrease of 71.28% year-on-year [1] - Accounts receivable reached 921 million yuan, representing a 1.49% increase year-on-year, with accounts receivable to net profit ratio at 1434.04% [1] Changes in Financial Items - Significant changes in financial items included a 62.42% decrease in notes receivable due to maturity [2] - Accounts payable decreased by 33.49% due to maturing payables [2] - Tax liabilities decreased by 37.83% due to payments of VAT and income tax [2] - Other payables decreased by 50.57% due to the repurchase of restricted stock [2] - Financial expenses increased by 43.13% due to reduced interest income [2] - Net cash flow from operating activities decreased by 71.44% due to increased cash payments for goods and services [2] Business Evaluation - The company's return on invested capital (ROIC) was 3.85%, indicating weak capital returns, with a historical median ROIC of 9.41% since its listing [3] - The company's cash assets are considered healthy, but attention is needed on cash flow and accounts receivable management [3] - The business model relies heavily on research and development, necessitating further investigation into the underlying drivers of this approach [3]
回天新材2025年中报简析:营收净利润同比双双增长,公司应收账款体量较大
Zheng Quan Zhi Xing· 2025-08-20 22:41
据证券之星公开数据整理,近期回天新材(300041)发布2025年中报。截至本报告期末,公司营业总收入 21.68亿元,同比上升7.72%,归母净利润1.43亿元,同比上升4.18%。按单季度数据看,第二季度营业 总收入10.97亿元,同比上升5.15%,第二季度归母净利润6097.93万元,同比上升6.18%。本报告期回天 新材公司应收账款体量较大,当期应收账款占最新年报归母净利润比达1374.08%。 本次财报公布的各项数据指标表现尚佳。其中,毛利率22.46%,同比增17.68%,净利率6.66%,同比减 1.78%,销售费用、管理费用、财务费用总计2.36亿元,三费占营收比10.87%,同比增19.17%,每股净 资产4.92元,同比减0.75%,每股经营性现金流0.05元,同比增172.3%,每股收益0.25元,同比增3.75% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 20.13亿 | 21.68亿 | 7.72% | | 归母净利润(元) | 1.37亿 | 1.43亿 | 4.18% | | ...
华邦健康2025年中报简析:营收净利润同比双双增长
Zheng Quan Zhi Xing· 2025-08-20 22:40
据证券之星公开数据整理,近期华邦健康(002004)发布2025年中报。根据财报显示,华邦健康营收净利 润同比双双增长。截至本报告期末,公司营业总收入59.45亿元,同比上升0.39%,归母净利润3.88亿 元,同比上升23.9%。按单季度数据看,第二季度营业总收入31.24亿元,同比上升3.91%,第二季度归 母净利润2.04亿元,同比上升29.22%。 本次财报公布的各项数据指标表现尚佳。其中,毛利率36.28%,同比减1.18%,净利率9.25%,同比增 29.12%,销售费用、管理费用、财务费用总计13.03亿元,三费占营收比21.92%,同比减5.06%,每股净 资产4.92元,同比减2.2%,每股经营性现金流0.27元,同比增46.1%,每股收益0.2元,同比增24.15% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 59.22 亿 | 59.45 亿 | 0.39% | | 归母净利润(元) | 3.14Z | 3.88 Z | 23.90% | | 扣非净利润(元) | 2.96亿 | 3.4 ...
双塔食品2025年中报简析:营收净利润同比双双增长,公司应收账款体量较大
Zheng Quan Zhi Xing· 2025-08-20 22:40
据证券之星公开数据整理,近期双塔食品(002481)发布2025年中报。截至本报告期末,公司营业总收 入10.47亿元,同比上升6.18%,归母净利润5436.35万元,同比上升0.89%。按单季度数据看,第二季度 营业总收入5.47亿元,同比下降0.69%,第二季度归母净利润4542.88万元,同比上升270.64%。本报告 期双塔食品公司应收账款体量较大,当期应收账款占最新年报归母净利润比达261.53%。 本次财报公布的各项数据指标表现一般。其中,毛利率17.92%,同比减22.29%,净利率5.12%,同比减 4.43%,销售费用、管理费用、财务费用总计8191.32万元,三费占营收比7.82%,同比减15.68%,每股 净资产2.13元,同比增1.25%,每股经营性现金流-0.14元,同比减169.99%,每股收益0.04元,同比增 0.92% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 9.86 Z | 10.47亿 | 6.18% | | 归母净利润(元) | 5388.29万 | 5436.3 ...
常山北明2025年中报简析:营收上升亏损收窄,盈利能力上升
Zheng Quan Zhi Xing· 2025-08-19 23:00
| 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 28.46 Z | 37.22 亿 | 30.77% | | 归母浄利润(元) | -2.54亿 | -9299.44万 | 63.39% | | 扣非净利润(元) | -3.2 Z- | -1.26 Z | 60.55% | | 货币资金(元) | 16.24亿 | 18.12 Z | 11.60% | | 应收账款(元) | 25.92亿 | 29.23 亿 | 12.78% | | 有息负债(元) | 53.94亿 | 71.64亿 | 32.82% | | 毛利率 | 10.04% | 10.99% | 9.52% | | 净利率 | -9.49% | -2.53% | 73.32% | | 三费占营收比 | 15.76% | 10.06% | -36.13% | | 每股净资产 (元) | 3.51 | 3.3 | -5.92% | | 每股收益(元) | -0.16 | -0.06 | 63.37% | | 每股经营性现金流(元) | -0.78 | - ...
康强电子2025年中报简析:净利润同比增长26.23%,盈利能力上升
Zheng Quan Zhi Xing· 2025-08-19 23:00
证券之星价投圈财报分析工具显示:业务评价:公司去年的ROIC为4.87%,资本回报率不强。去年的净 利率为4.23%,算上全部成本后,公司产品或服务的附加值不高。从历史年报数据统计来看,公司近10 年来中位数ROIC为7.19%,中位投资回报较弱,其中最惨年份2015年的ROIC为-1.89%,投资回报极 差。公司历史上的财报相对一般,公司上市来已有年报17份,亏损年份1次,需要仔细研究下有无特殊 原因。商业模式:公司业绩主要依靠研发驱动。需要仔细研究这类驱动力背后的实际情况。 财务报表中对有大幅变动的财务项目的原因说明如下:所得税费用变动幅度为143.63%,原因:本期应纳 税所得额增加。经营活动产生的现金流量净额变动幅度为2073.78%,原因:本期销售回款加快,用票据支 付货款增加致现金流出减少,以及政府补助增加。投资活动产生的现金流量净额变动幅度为-194.62%, 原因:本期购买大额存单及长期资产支出增加。筹资活动产生的现金流量净额变动幅度为32.59%,原因:本 期偿还债务减少。现金及现金等价物净增加额变动幅度为342.98%,原因:本期经营活动产生的现金流量 净额增加。 据证券之星公开数据整理, ...